Mgc Pharmaceuticals Ltd. (MGCLF) has released an update.
Argent BioPharma Ltd, a drug discovery company, has officially changed its name following shareholder approval and has welcomed Dr. Shlomo Sadoun with extensive pharmaceutical experience to its advisory board. The company reported that its revenue for the March quarter was consistent with average quarterly sales and has $1.999 million in cash reserves at quarter’s end. Additionally, Argent BioPharma has renegotiated terms for its convertible notes with Mercer Street Global Opportunity Fund, potentially impacting future financial flexibility.
For further insights into MGCLF stock, check out TipRanks’ Stock Analysis page.
